Persistent idiopathic facial pain

Summary

Persistent idiopathic facial pain (MONDO:0018362) is a disease and 9 clinical trials. Top therapeutic interventions include betamethasone, bupivacaine, and dexamethasone. A subtype of nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 11
• Clinical trials: 9

Clinical features

Epidemiology

Prevalence records

3 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	4.4	Netherlands	Validated
Annual incidence	1-9 / 100 000	1	Germany	Validated
Lifetime Prevalence	1-5 / 10 000	30	Germany	Validated

Signs & symptoms

Clinical features (HPO)

11 HPO clinical features (Orphanet curated; top 11 by frequency):

HPO ID	Term	Frequency
HP:0000271	Abnormality of the face	Very frequent (80-99%)
HP:0012532	Chronic pain	Very frequent (80-99%)
HP:0025282	Dull	Frequent (30-79%)
HP:0000716	Depression	Occasional (5-29%)
HP:0000739	Anxiety	Occasional (5-29%)
HP:0003401	Paresthesia	Occasional (5-29%)
HP:0003489	Acute episodes of neuropathic symptoms	Occasional (5-29%)
HP:0007328	Impaired pain sensation	Occasional (5-29%)
HP:0032143	Burning mouth	Occasional (5-29%)
HP:0012639	Abnormal nervous system morphology	Excluded (0%)
HP:0003474	Somatic sensory dysfunction	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	persistent idiopathic facial pain
Mondo ID	MONDO:0018362
Orphanet	398147
ICD-10-CM	G50.1
ICD-11	1799118131
UMLS	C5191641
MedGen	1673850
GARD	0021649
Is cancer (heuristic)	no

Also known as: AFP · atypical facial pain · PIFP

Disease family

This is a subtype of nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › persistent idiopathic facial pain

Related subtypes (71): congenital nervous system disorder, central nervous system disorder, autoimmune disorder of the nervous system, cranial nerve neuropathy, peripheral nervous system disorder, neuronitis, diplegia of upper limb, retinal disorder, developmental disability, restless legs syndrome, movement disorder, toxic encephalopathy, Barre-Lieou syndrome, Gerstmann syndrome, drug-induced akathisia, drug-induced dyskinesia, stiff-person syndrome, Worster-Drought syndrome, corneal-cerebellar syndrome, pachygyria-intellectual disability-epilepsy syndrome, porencephaly-cerebellar hypoplasia-internal malformations syndrome, symmetrical thalamic calcifications, neonatal brainstem dysfunction, primary orthostatic hypotension, rippling muscle disease with myasthenia gravis, periodic paralysis, qualitative or quantitative protein defects in neuromuscular diseases, specific learning disability, cerebellar hypoplasia-tapetoretinal degeneration syndrome, locked-in syndrome, dopa-responsive dystonia, idiopathic recurrent stupor, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, spontaneous periodic hypothermia, Sydenham chorea, duplication of the pituitary gland, Balint syndrome, paraneoplastic neurologic syndrome, serotonin syndrome, hypothalamic adipsic hypernatraemia syndrome, exercise-induced malignant hyperthermia, perineural cyst, neuromuscular disease, neuromyelitis optica, AL amyloidosis, AA amyloidosis, neuroleptic malignant syndrome, infectious disorder of the nervous system, central nervous system malformation, synaptopathy, nervous system neoplasm, sensory ganglionopathy, radiculitis, wet beriberi, perceptual disorders, prepubertal anorexia nervosa, neurocutaneous syndrome, neurovascular disorder, Wallerian degeneration, nervous system injury, neurosarcoidosis, neuroendocrine disorder, tubulinopathy, atactic disorder, hereditary neurological disease, meningitis-retention syndrome, KIF1A related neurological disorder, neurological pain disorder, neurodevelopmental disorder, post 5-alpha-reductase inhibitors treatment syndrome, post-selective serotonin reuptake inhibitor sexual dysfunction

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02024724	PHASE4	COMPLETED	Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain
NCT01920087	PHASE2/PHASE3	WITHDRAWN	Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain
NCT04006821	PHASE2	UNKNOWN	PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
NCT04098796	PHASE2	UNKNOWN	PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07123233	Not specified	RECRUITING	An Innovative Cognitive-Behavioral Treatment For Chronic Orofacial Pain
NCT01746355	Not specified	COMPLETED	Assessment and Treatment Patients With Atypical Facial Pain Trough Repetitive Transcranial Magnetic Stimulation
NCT04775758	Not specified	UNKNOWN	Atypical Orofacial Pain Diagnostics and Differentiation.
NCT05257655	Not specified	COMPLETED	Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
NCT06496841	Not specified	COMPLETED	Transnasal Versus Suprazygomatic SPG Block in Persistant Idiopathic Facial Pain

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BETAMETHASONE	4	1
BUPIVACAINE	4	1
DEXAMETHASONE	4	1
TRIAMCINOLONE	4	1